Taysha Gene Therapies, Inc. (TSHA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Taysha Gene Therapies reported revenue of $9.8M, up 17.3% from $8.3M the year before. Net income was -$109.0M (a -1115.3% net margin), or -$0.34 per diluted share. Operating margin was -1130.6%. Operating activities generated -$93.1M of cash, leaving -$93.8M of free cash flow. At fiscal year end, Taysha Gene Therapies held $343.3M in total assets against $96.4M in total liabilities, including $319.8M of cash and equivalents.
Open the full interactive Taysha Gene Therapies financials → Quarterly statements, key ratios, valuation history and price charts.
Taysha Gene Therapies Key Stats
| Share Price | $3.58 |
|---|---|
| Market Cap | $1.32B |
| Revenue YoY Growth | +17.3% |
| 52-Week Range | $3.58 – $6.98 |
| Shares Outstanding | 369.0 million (basic, 2026 Q2) |
Taysha Gene Therapies Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $2.5M | $15.5M | $8.3M | $9.8M |
| Operating Income | -$43.0M | -$173.3M | -$162.4M | -$72.4M | -$91.5M | -$110.5M |
| Pre-Tax Income | -$60.0M | -$174.5M | -$166.0M | -$111.6M | -$89.3M | -$109.0M |
| Income Tax | $0 | — | $0 | $0 | $0 | $0 |
| Net Income | -$60.0M | -$174.5M | -$166.0M | -$111.6M | -$89.3M | -$109.0M |
| Diluted EPS | -$3.40 | -$4.64 | -$3.78 | -$0.96 | -$0.36 | -$0.34 |
Taysha Gene Therapies Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $5.5M | $0 | $0 |
| Net Income | -$32.7M | -$27.9M | -$42.4M | -$46.6M |
| Diluted EPS | -$0.09 | -$0.09 | -$0.12 | -$0.13 |
Taysha Gene Therapies Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $251.3M | $149.1M | $87.9M | $143.9M | $139.0M | $319.8M |
| Current Assets | $257.9M | $159.6M | $96.4M | $149.9M | $142.1M | $324.6M |
| Total Assets | $258.9M | $214.0M | $126.3M | $172.7M | $160.4M | $343.3M |
| Current Liabilities | $7.1M | $51.7M | $62.8M | $36.8M | $26.2M | $26.6M |
| Total Long-Term Debt | — | $37.2M | $38.0M | $40.5M | $43.9M | $50.1M |
| Total Liabilities | $7.6M | $118.6M | $125.3M | $97.8M | $88.8M | $96.4M |
| Shareholders' Equity | $251.3M | $95.4M | $949,000 | $74.9M | $71.5M | $246.9M |
Taysha Gene Therapies Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$30.7M | -$117.0M | -$88.4M | -$73.0M | -$81.2M | -$93.1M |
| Cash From Investing | -$9.1M | -$21.6M | -$24.9M | -$7.4M | -$363,000 | -$604,000 |
| Cash From Financing | $291.1M | $39.1M | $52.1M | $136.4M | $76.7M | $274.6M |
| Free Cash Flow | -$30.8M | -$132.3M | -$109.0M | -$76.9M | -$81.6M | -$93.8M |
Figures from Taysha Gene Therapies' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Taysha Gene Therapies financials page for every line item.
Taysha Gene Therapies Company Profile
| Ticker | TSHA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Dallas, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001806310 |
Frequently Asked Questions
What was Taysha Gene Therapies' revenue in fiscal 2025?
Taysha Gene Therapies (TSHA) reported revenue of $9.8M for fiscal 2025.
What is Taysha Gene Therapies' annual revenue history?
Taysha Gene Therapies' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $2.5M; 2023: $15.5M; 2024: $8.3M; 2025: $9.8M.
What was Taysha Gene Therapies' net income in fiscal 2025?
Taysha Gene Therapies reported net income of -$109.0M for fiscal 2025.
What was Taysha Gene Therapies' earnings per share (EPS) in fiscal 2025?
Taysha Gene Therapies' diluted EPS was -$0.34 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Taysha Gene Therapies generate in fiscal 2025?
Taysha Gene Therapies generated -$93.8M of free cash flow in fiscal 2025.
What was Taysha Gene Therapies' revenue last quarter?
In its most recent reported quarter (2026 Q2), Taysha Gene Therapies reported revenue of $0.
How much debt does Taysha Gene Therapies have?
Taysha Gene Therapies reported $50.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Taysha Gene Therapies are outstanding?
Taysha Gene Therapies reported a weighted average of 369.0 million basic shares outstanding in 2026 Q2.
What is Taysha Gene Therapies' market cap?
Based on its latest closing price, Taysha Gene Therapies (TSHA) has a market capitalization of about $1.32B.
When does Taysha Gene Therapies' fiscal year end?
Taysha Gene Therapies' fiscal year end, as registered with the SEC, is December 31.
Where is Taysha Gene Therapies headquartered?
Taysha Gene Therapies lists its business address in Dallas, Texas in its SEC filings.
Taysha Gene Therapies Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →